Białaczka włochatokomórkowa – Zapobieganie i profilaktyka

Białaczka włochatokomórkowa
Zapobieganie i profilaktyka

Białaczka włochatokomórkowa (HCL) jest rzadkim schorzeniem hematologicznym, dla którego nie istnieją znane metody prewencji pierwotnej. Choroba i jej leczenie, zwłaszcza analogami puryn (kladrybina, pentostatyna), prowadzą do głębokiej i długotrwałej immunosupresji, co znacząco zwiększa ryzyko infekcji oportunistycznych, w tym zakażeń wirusem HSV, VZV oraz Pneumocystis jirovecii (PJP). Profilaktyka wtórna obejmuje stosowanie leków przeciwbakteryjnych, przeciwwirusowych i przeciwgrzybiczych, a także szczepienia przeciwko grypie, zapaleniu płuc i COVID-19, z wykluczeniem szczepionek żywych ze względu na ryzyko u pacjentów z osłabionym układem odpornościowym. Szczepienia mogą być opóźnione nawet do 6 miesięcy po terapii przeciwciałami anty-CD20, a skuteczność odpowiedzi immunologicznej pozostaje nie do końca poznana.

Profilaktyka Białaczki Włochatokomórkowej

Profilaktyka infekcji u pacjentów z białaczką włochatokomórkową
Farmakologiczna profilaktyka przeciwinfekcyjna
Szczepienia ochronne
Profilaktyka COVID-19 u pacjentów z białaczką włochatokomórkową
Reaktywacja wirusowego zapalenia wątroby typu B
Edukacja pacjentów
Ogólne zalecenia prozdrowotne
Ograniczenia i przyszłe kierunki badań
Kolejne rozdziały

Profilaktyka Białaczki Włochatokomórkowej

Białaczka włochatokomórkowa (HCL) to rzadkie schorzenie hematologiczne, które nie ma obecnie znanych metod prewencji pierwotnej. Według dostępnych danych naukowych nie istnieją jednoznacznie potwierdzone sposoby zapobiegania rozwojowi tej choroby, a jej czynniki ryzyka pozostają poza kontrolą pacjenta.¹² W przeciwieństwie do innych nowotworów, HCL nie jest związana ze stylem życia, ani nie jest chorobą zakaźną, której można by się zarazić od innej osoby.³

Profilaktyka infekcji u pacjentów z białaczką włochatokomórkową

Infekcje stanowią najczęstszą przyczynę zgonów u pacjentów z klasyczną postacią białaczki włochatokomórkowej (cHCL).⁴ Zarówno sama choroba, jak i standardowe metody jej leczenia, szczególnie analogi puryn (kladrybina, pentostatyna), prowadzą do głębokiej i długotrwałej immunosupresji, zwiększając podatność na infekcje.⁵ W związku z tym profilaktyka przeciwinfekcyjna odgrywa kluczową rolę w prowadzeniu pacjentów z HCL.

Farmakologiczna profilaktyka przeciwinfekcyjna

Leczenie profilaktyczne (profilaktyka wtórna) w HCL ma na celu zapobieganie potencjalnym infekcjom podczas lub po leczeniu zasadniczym. Lekarze zalecają stosowanie leków profilaktycznych, szczególnie podczas terapii analogami nukleozydów purynowych, które znacząco osłabiają układ odpornościowy.⁶ Rekomendowana jest profilaktyka przeciwbakteryjna, przeciwwirusowa i przeciwgrzybicza:

Profilaktyka zakażeń wirusem opryszczki pospolitej (HSV) ⁷
Profilaktyka zakażeń wirusem ospy wietrznej i półpaśca (VZV) ⁸
Profilaktyka zapalenia płuc wywołanego przez Pneumocystis jirovecii (PJP) ⁹

Warto podkreślić, że nawet krótkookresowa (jednotygodniowa) terapia analogami nukleozydów purynowych niesie ze sobą istotne ryzyko późnych zakażeń oportunistycznych, reaktywacji wirusów oraz zapalenia płuc wywołanego przez Pneumocystis jirovecii, co uzasadnia stosowanie profilaktycznej antybiotykoterapii.¹⁰

Szczepienia ochronne

Szczepienia stanowią istotny element profilaktyki infekcji u pacjentów z HCL, choć ich skuteczność może być ograniczona z powodu zaburzeń immunologicznych związanych z chorobą i leczeniem. Lekarze zazwyczaj zalecają następujące szczepienia:¹¹

Coroczne szczepienie przeciwko grypie
Szczepienie przeciwko zapaleniu płuc
Szczepienie przeciwko COVID-19

Pacjenci z HCL nie powinni otrzymywać szczepionek żywych, które zawierają osłabioną wersję patogenu, gdyż mogą one stanowić zagrożenie dla osób z osłabionym układem odpornościowym.¹² Zaleca się konsultację z lekarzem w celu określenia, które szczepionki są bezpieczne, a których należy unikać.

Warto zauważyć, że brak jest jednoznacznych danych potwierdzających skuteczność odpowiedzi na szczepienia u pacjentów z HCL, co wskazuje na konieczność dalszych badań w tym zakresie.¹³ Ponadto, szczepienie pacjentów z HCL może być opóźnione nawet do 6 miesięcy lub dłużej po ostatnim zastosowaniu przeciwciał anty-CD20.¹⁴

Profilaktyka COVID-19 u pacjentów z białaczką włochatokomórkową

W kontekście pandemii COVID-19 opracowano specjalne zalecenia dla pacjentów z HCL, uwzględniające ich zwiększoną podatność na ciężki przebieg tej infekcji.¹⁵ Pacjentom zdecydowanie zaleca się przestrzeganie krajowych i lokalnych wytycznych dotyczących zapobiegania rozprzestrzenianiu się SARS-CoV-2, które obejmują:¹⁶

Zachowanie dystansu społecznego
Przestrzeganie higieny rąk
Noszenie masek chirurgicznych zakrywających nos i usta

Dodatkowo, pacjenci z HCL powinni:¹⁷

Wykorzystywać wszystkie dostępne opcje komunikacji z hematologami bez kontaktu fizycznego
Ograniczać potencjalną ekspozycję na SARS-CoV-2 w środowisku opieki zdrowotnej
W przypadku zdiagnozowania zakażenia SARS-CoV-2 poddać się samoizolacji lub izolacji w pojedynczym pokoju
Korzystać z testów PCR w kierunku SARS-CoV-2 w przypadku zwiększonego ryzyka infekcji lub po udokumentowanej ekspozycji

Reaktywacja wirusowego zapalenia wątroby typu B

U pacjentów z HCL, którzy przebyli wcześniej zakażenie wirusem zapalenia wątroby typu B (HBV), istnieje ryzyko reaktywacji wirusa podczas lub po leczeniu immunosupresyjnym. Zarejestrowano przypadki odwrotnej serokonwersji do zakażenia HBV u pacjentów onkohematologicznych otrzymujących terapię cytotoksyczną lub allogeniczny przeszczep szpiku kostnego.¹⁸

Opisano przypadek pacjenta z HCL, HBsAg-ujemnego, anty-HBc-dodatniego, u którego rozwinęło się ostre wirusowe zapalenie wątroby typu B ponad rok po ostatnim kursie leczenia 2-CdA i 6 miesięcy po splenektomii, podczas terapii interferonem. Ostre zapalenie wątroby typu B szybko ustąpiło po zastosowaniu lamiwudyny, co doprowadziło do eliminacji wirusa.¹⁹ Przypadek ten podkreśla znaczenie monitorowania statusu wirusologicznego pacjentów z HCL oraz potencjalną konieczność profilaktyki przeciwwirusowej u osób z przebytym zakażeniem HBV.

Edukacja pacjentów

Istotnym elementem profilaktyki jest edukacja pacjentów na temat zapobiegania infekcjom oraz objawów, które mogą wymagać pilnej interwencji medycznej, takich jak:²⁰

Gorączka podczas neutropenii
Wysypka wskazująca na zakażenie wirusem varicella zoster
Inne niepokojące objawy świadczące o infekcji

Ogólne zalecenia prozdrowotne

Choć nie ma bezpośrednich dowodów na to, że poniższe działania zapobiegają rozwojowi HCL, ogólne zalecenia prozdrowotne mogą przyczyniać się do poprawy ogólnego stanu zdrowia pacjentów:²¹²²

Unikanie palenia tytoniu i ograniczenie spożycia alkoholu – te czynniki zostały powiązane ze zwiększonym ryzykiem różnych nowotworów, w tym białaczek
Minimalizowanie ekspozycji na potencjalnie szkodliwe substancje chemiczne, jak pestycydy i rozpuszczalniki – osoby pracujące w miejscach narażonych na kontakt z chemikaliami powinny przestrzegać zasad bezpieczeństwa i stosować środki ochronne
Regularne badania kontrolne – umożliwiają wczesne rozpoznanie i leczenie potencjalnych problemów zdrowotnych
Utrzymywanie zdrowego stylu życia – regularna aktywność fizyczna, zbilansowana dieta, odpowiednia ilość snu i zarządzanie stresem mogą wspierać układ odpornościowy

Ograniczenia i przyszłe kierunki badań

Warto podkreślić, że obecnie nie określono specyficznych strategii zapobiegania infekcjom u pacjentów z HCL w badaniach klinicznych, a praktyki różnią się między ośrodkami. Ocena strategii zapobiegania i leczenia infekcji stanowi obszar wymagający dalszych badań.²³ Brak jest również danych wskazujących na to, że pacjenci z HCL odpowiadają na szczepienia, co wskazuje na potrzebę dalszych badań nad skutecznością strategii zapobiegania poprzez szczepienia w tej grupie chorych.²⁴

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Hairy cell leukemia
https://adamcertificationdemo.adam.com/content.aspx?productid=140&isarticlelink=false&pid=1&gid=000592
There is no known way to prevent this disease.
#2 Hairy Cell Leukemia Symptoms & Treatment | Baptist Health
https://www.baptisthealth.com/care-services/conditions-treatments/hairy-cell-leukemia
Risk factors cannot be controlled. Hairy cell leukemia is not affected by lifestyle habits nor can it be caught from someone.
#3 Hairy Cell Leukemia Symptoms & Treatment | Baptist Health
https://www.baptisthealth.com/care-services/conditions-treatments/hairy-cell-leukemia
Risk factors cannot be controlled. Hairy cell leukemia is not affected by lifestyle habits nor can it be caught from someone.
#4 Consensus guidelines for classic Hairy Cell Leukemia: treatment at relapse, and infection prevention and treatment
https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
Infection is the most common cause of death in HCLc patients. […] Patients need to be educated about how to prevent infection and the symptoms to be aware of which may require medical attention (such as fever during neutropenia, or rash indicative of varicella zoster infection). Currently, no specific prevention strategies have been defined in clinical trials and practices vary between institutions, therefore evaluation of prevention and infection treatment strategies is an area of much needed research. […] Moreover, there is no data indicating that patients respond to vaccines; further investigation into the effectiveness of vaccination prevention strategies is required.
#5 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines | Leukemia
https://www.nature.com/articles/s41375-021-01257-7
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. […] The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19. […] Cancer patients are strongly recommended to follow the national and local guidelines for prevention of the further spread of SARS-CoV-2. These include social distancing, hand hygiene, and surgical masks covering nose and mouths.
#6 Parting Advice on Hairy Cell Leukemia Management
https://www.onclive.com/view/parting-advice-on-hairy-cell-leukemia-management
Both purine nucleoside analogs, cladribine and pentostatin, result in very high complete response [CR] rates. […] However, these drugs are very immunocompromising, and patients may still be at risk of viral infections or opportunistic infections. So we typically will provide antimicrobial prophylaxis, especially for HSV [herpes simplex virus], VZV [varicella zoster virus], and PJP [pneumocystis jirovecii pneumonia]. […] To me, the most important thing for community oncologists who are treating hairy cell leukemia is to recognize the potential risks of highly active drugs. In the case of purine nucleoside drugs, late opportunistic infection, viral reactivation, and pneumocystis pneumonia are of such a frequency that prophylactic antibiotics really need to be given with even a one-week therapy with a purine nucleoside analog.
#7 Parting Advice on Hairy Cell Leukemia Management
https://www.onclive.com/view/parting-advice-on-hairy-cell-leukemia-management
Both purine nucleoside analogs, cladribine and pentostatin, result in very high complete response [CR] rates. […] However, these drugs are very immunocompromising, and patients may still be at risk of viral infections or opportunistic infections. So we typically will provide antimicrobial prophylaxis, especially for HSV [herpes simplex virus], VZV [varicella zoster virus], and PJP [pneumocystis jirovecii pneumonia]. […] To me, the most important thing for community oncologists who are treating hairy cell leukemia is to recognize the potential risks of highly active drugs. In the case of purine nucleoside drugs, late opportunistic infection, viral reactivation, and pneumocystis pneumonia are of such a frequency that prophylactic antibiotics really need to be given with even a one-week therapy with a purine nucleoside analog.
#8 Parting Advice on Hairy Cell Leukemia Management
https://www.onclive.com/view/parting-advice-on-hairy-cell-leukemia-management
Both purine nucleoside analogs, cladribine and pentostatin, result in very high complete response [CR] rates. […] However, these drugs are very immunocompromising, and patients may still be at risk of viral infections or opportunistic infections. So we typically will provide antimicrobial prophylaxis, especially for HSV [herpes simplex virus], VZV [varicella zoster virus], and PJP [pneumocystis jirovecii pneumonia]. […] To me, the most important thing for community oncologists who are treating hairy cell leukemia is to recognize the potential risks of highly active drugs. In the case of purine nucleoside drugs, late opportunistic infection, viral reactivation, and pneumocystis pneumonia are of such a frequency that prophylactic antibiotics really need to be given with even a one-week therapy with a purine nucleoside analog.
#9 Parting Advice on Hairy Cell Leukemia Management
https://www.onclive.com/view/parting-advice-on-hairy-cell-leukemia-management
Both purine nucleoside analogs, cladribine and pentostatin, result in very high complete response [CR] rates. […] However, these drugs are very immunocompromising, and patients may still be at risk of viral infections or opportunistic infections. So we typically will provide antimicrobial prophylaxis, especially for HSV [herpes simplex virus], VZV [varicella zoster virus], and PJP [pneumocystis jirovecii pneumonia]. […] To me, the most important thing for community oncologists who are treating hairy cell leukemia is to recognize the potential risks of highly active drugs. In the case of purine nucleoside drugs, late opportunistic infection, viral reactivation, and pneumocystis pneumonia are of such a frequency that prophylactic antibiotics really need to be given with even a one-week therapy with a purine nucleoside analog.
#10 Parting Advice on Hairy Cell Leukemia Management
https://www.onclive.com/view/parting-advice-on-hairy-cell-leukemia-management
Both purine nucleoside analogs, cladribine and pentostatin, result in very high complete response [CR] rates. […] However, these drugs are very immunocompromising, and patients may still be at risk of viral infections or opportunistic infections. So we typically will provide antimicrobial prophylaxis, especially for HSV [herpes simplex virus], VZV [varicella zoster virus], and PJP [pneumocystis jirovecii pneumonia]. […] To me, the most important thing for community oncologists who are treating hairy cell leukemia is to recognize the potential risks of highly active drugs. In the case of purine nucleoside drugs, late opportunistic infection, viral reactivation, and pneumocystis pneumonia are of such a frequency that prophylactic antibiotics really need to be given with even a one-week therapy with a purine nucleoside analog.
#11 Supportive treatments for hairy cell leukaemia | Cancer Research UK
https://www.cancerresearchuk.org/about-cancer/hairy-cell-leukaemia/treatment/supportive
Doctors sometimes suggest you take medicines before you get an infection. This is to try to prevent it from happening. These are called prophylactic medicines. Prophylactic (pronounced prof-il-ak-tik) means preventative. […] You might have medicines to prevent bacterial or viral infections. […] Vaccines are a way of protecting you against certain infections. Your doctor is likely to suggest that you have: a yearly flu vaccine, a vaccine to prevent pneumonia, a coronavirus vaccine. […] You shouldn’t have live vaccines if you have HCL. This is because live vaccines contain a very weak version of the illness. Your doctor can tell you which vaccines are safe, and which ones to avoid.
#12 Supportive treatments for hairy cell leukaemia | Cancer Research UK
https://www.cancerresearchuk.org/about-cancer/hairy-cell-leukaemia/treatment/supportive
Doctors sometimes suggest you take medicines before you get an infection. This is to try to prevent it from happening. These are called prophylactic medicines. Prophylactic (pronounced prof-il-ak-tik) means preventative. […] You might have medicines to prevent bacterial or viral infections. […] Vaccines are a way of protecting you against certain infections. Your doctor is likely to suggest that you have: a yearly flu vaccine, a vaccine to prevent pneumonia, a coronavirus vaccine. […] You shouldn’t have live vaccines if you have HCL. This is because live vaccines contain a very weak version of the illness. Your doctor can tell you which vaccines are safe, and which ones to avoid.
#13 Consensus guidelines for classic Hairy Cell Leukemia: treatment at relapse, and infection prevention and treatment
https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
Infection is the most common cause of death in HCLc patients. […] Patients need to be educated about how to prevent infection and the symptoms to be aware of which may require medical attention (such as fever during neutropenia, or rash indicative of varicella zoster infection). Currently, no specific prevention strategies have been defined in clinical trials and practices vary between institutions, therefore evaluation of prevention and infection treatment strategies is an area of much needed research. […] Moreover, there is no data indicating that patients respond to vaccines; further investigation into the effectiveness of vaccination prevention strategies is required.
#14 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines | Leukemia
https://www.nature.com/articles/s41375-021-01257-7
Several highly effective vaccines have been recently developed with specific focus on decreasing the risks of acquiring this virus, and vigorous efforts at immunization are underway. […] Vaccination in HCL patients may be delayed to up to 6 months or longer after the last application of anti-CD20 antibodies. […] HCL patients should use all available options to communicate with their hematologists without physical contact and to reduce potential exposure to SARS-CoV-2 in the health care environment. […] HCL patients diagnosed with SARS-CoV-2 infection should undergo either self-quarantine, single room, or cohort isolation. […] SARS-CoV-2 PCR testing should be available to all HCL patients at increased risk for infection and for monitoring after documented exposure. […] Documentation of the presence of IgG antibodies in patients who have recovered will be useful in understanding the response to this infection.
#15 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines | Leukemia
https://www.nature.com/articles/s41375-021-01257-7
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. […] The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19. […] Cancer patients are strongly recommended to follow the national and local guidelines for prevention of the further spread of SARS-CoV-2. These include social distancing, hand hygiene, and surgical masks covering nose and mouths.
#16 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines | Leukemia
https://www.nature.com/articles/s41375-021-01257-7
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. […] The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19. […] Cancer patients are strongly recommended to follow the national and local guidelines for prevention of the further spread of SARS-CoV-2. These include social distancing, hand hygiene, and surgical masks covering nose and mouths.
#17 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines | Leukemia
https://www.nature.com/articles/s41375-021-01257-7
Several highly effective vaccines have been recently developed with specific focus on decreasing the risks of acquiring this virus, and vigorous efforts at immunization are underway. […] Vaccination in HCL patients may be delayed to up to 6 months or longer after the last application of anti-CD20 antibodies. […] HCL patients should use all available options to communicate with their hematologists without physical contact and to reduce potential exposure to SARS-CoV-2 in the health care environment. […] HCL patients diagnosed with SARS-CoV-2 infection should undergo either self-quarantine, single room, or cohort isolation. […] SARS-CoV-2 PCR testing should be available to all HCL patients at increased risk for infection and for monitoring after documented exposure. […] Documentation of the presence of IgG antibodies in patients who have recovered will be useful in understanding the response to this infection.
#18
https://link.springer.com/article/10.1007/s15010-006-4150-8
The reverse seroconversion to hepatitis B virus infection has been sporadically described in onco-haematological patients receiving cytotoxic therapy or allogeneic bone marrow transplantation and can be associated with the development of acute icteric hepatitis. […] We present a male HBsAg-negative, anti-HBc-positive patient with Hairy Cell Leukemia who developed acute B hepatitis more than 1 year after the last course of 2-CdA and 6 months after splenectomy, while the patient was receiving therapy with IFNr. […] The acute B hepatitis promptly responded to lamivudine therapy followed by viral clearance.
#19
https://link.springer.com/article/10.1007/s15010-006-4150-8
The reverse seroconversion to hepatitis B virus infection has been sporadically described in onco-haematological patients receiving cytotoxic therapy or allogeneic bone marrow transplantation and can be associated with the development of acute icteric hepatitis. […] We present a male HBsAg-negative, anti-HBc-positive patient with Hairy Cell Leukemia who developed acute B hepatitis more than 1 year after the last course of 2-CdA and 6 months after splenectomy, while the patient was receiving therapy with IFNr. […] The acute B hepatitis promptly responded to lamivudine therapy followed by viral clearance.
#20 Consensus guidelines for classic Hairy Cell Leukemia: treatment at relapse, and infection prevention and treatment
https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
Infection is the most common cause of death in HCLc patients. […] Patients need to be educated about how to prevent infection and the symptoms to be aware of which may require medical attention (such as fever during neutropenia, or rash indicative of varicella zoster infection). Currently, no specific prevention strategies have been defined in clinical trials and practices vary between institutions, therefore evaluation of prevention and infection treatment strategies is an area of much needed research. […] Moreover, there is no data indicating that patients respond to vaccines; further investigation into the effectiveness of vaccination prevention strategies is required.
#21 Hairy Cell Leukaemia: Symptoms, Treatment & Survival Rate
https://www.hexahealth.com/condition/hairy-cell-leukaemia
At present, there are no known specific measures for preventing the development of hairy cell leukaemia. Since the exact causes of HCL are not fully understood, there are no targeted strategies for its prevention. However, the following preventive measures can help reduce the risk of the disease: […] Avoid Smoking and Drinking Alcohol: Cigarette smoking and alcohol consumption have been linked to an increased risk of various cancers, including leukaemia. Quitting smoking and limiting alcohol intake is crucial for reducing the risk of developing HCL. […] Avoid Exposure to Harmful Chemicals: Minimising exposure to potentially harmful chemicals, like pesticides and solvents, can benefit overall health. Individuals who work in places with chemical exposure should follow safety guidelines and use protective measures.
#22 Hairy Cell Leukaemia: Symptoms, Treatment & Survival Rate
https://www.hexahealth.com/condition/hairy-cell-leukaemia
Regular Medical Checkups: Medical checkups at frequent intervals allow for early diagnosis and management of potential health concerns. […] Maintain a Healthy Lifestyle: Regular exercise, a balanced diet, adequate sleep, and stress management may help support the immune system, which is vital for combating diseases.
#23 Consensus guidelines for classic Hairy Cell Leukemia: treatment at relapse, and infection prevention and treatment
https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
Infection is the most common cause of death in HCLc patients. […] Patients need to be educated about how to prevent infection and the symptoms to be aware of which may require medical attention (such as fever during neutropenia, or rash indicative of varicella zoster infection). Currently, no specific prevention strategies have been defined in clinical trials and practices vary between institutions, therefore evaluation of prevention and infection treatment strategies is an area of much needed research. […] Moreover, there is no data indicating that patients respond to vaccines; further investigation into the effectiveness of vaccination prevention strategies is required.
#24 Consensus guidelines for classic Hairy Cell Leukemia: treatment at relapse, and infection prevention and treatment
https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
Infection is the most common cause of death in HCLc patients. […] Patients need to be educated about how to prevent infection and the symptoms to be aware of which may require medical attention (such as fever during neutropenia, or rash indicative of varicella zoster infection). Currently, no specific prevention strategies have been defined in clinical trials and practices vary between institutions, therefore evaluation of prevention and infection treatment strategies is an area of much needed research. […] Moreover, there is no data indicating that patients respond to vaccines; further investigation into the effectiveness of vaccination prevention strategies is required.